ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT)
CUSIP: H0036K147
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Shares, par value CHF 0.08 per share
- Shares outstanding
- 128,210,515
- Total 13F shares
- 51,801,951
- Share change
- +17,080,751
- Total reported value
- $163,693,841
- Put/Call ratio
- 20%
- Price per share
- $3.16
- Number of holders
- 73
- Value change
- +$51,364,315
- Number of buys
- 56
- Number of sells
- 13
Quarterly Holders Quick Answers
What is CUSIP H0036K147?
CUSIP H0036K147 identifies ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP H0036K147:
Top shareholders of ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC |
13F
|
Company |
12%
|
15,269,217
|
$68,558,784 | — | 31 Mar 2024 | |
| Prosight Management, LP |
13F
|
Company |
5.5%
|
7,050,300
|
$31,655,847 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
2.1%
|
2,720,395
|
$12,214,573 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.2%
|
1,540,509
|
$6,916,885 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.93%
|
1,193,847
|
$5,360,372 | — | 31 Mar 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.79%
|
1,010,437
|
$4,536,862 | — | 31 Mar 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.78%
|
1,000,000
|
$4,490,000 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.74%
|
952,464
|
$4,276,563 | — | 31 Mar 2024 | |
| Vantage Consulting Group Inc |
13F
|
Company |
0.66%
|
850,737
|
$3,819,809 | — | 31 Mar 2024 | |
| Blue Owl Capital Holdings LP |
13F
|
Company |
0.57%
|
733,568
|
$3,293,720 | — | 31 Mar 2024 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.39%
|
501,222
|
$2,250,487 | — | 31 Mar 2024 | |
| Monashee Investment Management LLC |
13F
|
Company |
0.39%
|
500,000
|
$2,245,000 | — | 31 Mar 2024 | |
| GCM Grosvenor Holdings, LLC |
13F
|
Company |
0.32%
|
410,888
|
$1,844,887 | — | 31 Mar 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.19%
|
243,243
|
$1,092,161 | — | 31 Mar 2024 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.09%
|
120,775
|
$542,280 | — | 31 Mar 2024 | |
| Florida Trust Wealth Management Co |
13F
|
Company |
0.08%
|
103,000
|
$462,470 | — | 31 Mar 2024 | |
| Composition Wealth, LLC |
13F
|
Company |
0.07%
|
84,496
|
$379,387 | — | 31 Mar 2024 | |
| Hennion & Walsh Asset Management, Inc. |
13F
|
Company |
0.06%
|
70,636
|
$317,156 | — | 31 Mar 2024 | |
| Magnetar Financial LLC |
13F
|
Company |
0.04%
|
55,762
|
$250,371 | — | 31 Mar 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.04%
|
54,913
|
$246,559 | — | 31 Mar 2024 | |
| DLK Investment Management, LLC |
13F
|
Company |
0.03%
|
33,155
|
$148,866 | — | 31 Mar 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.02%
|
26,984
|
$121,158 | — | 31 Mar 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.02%
|
26,921
|
$120,875 | — | 31 Mar 2024 | |
| XTX Topco Ltd |
13F
|
Company |
0.02%
|
24,829
|
$111,482 | — | 31 Mar 2024 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.02%
|
23,765
|
$106,705 | — | 31 Mar 2024 | |
| Saxony Capital Management, LLC |
13F
|
Company |
0.02%
|
20,623
|
$92,597 | — | 31 Mar 2024 | |
| COMMONWEALTH EQUITY SERVICES, LLC |
13F
|
Company |
0.01%
|
18,817
|
$84,000 | — | 31 Mar 2024 | |
| SIMPLEX TRADING, LLC |
13F
|
Company |
0.01%
|
14,755
|
$66,000 | — | 31 Mar 2024 | |
| AVISO WEALTH MANAGEMENT |
13F
|
Company |
0.01%
|
10,468
|
$47,001 | — | 31 Mar 2024 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.01%
|
8,000
|
$35,920 | — | 31 Mar 2024 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0%
|
4,787
|
$21,494 | — | 31 Mar 2024 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0%
|
3,030
|
$14,000 | — | 31 Mar 2024 | |
| Eagle Bay Advisors LLC |
13F
|
Company |
0%
|
670
|
$3,008 | — | 31 Mar 2024 | |
| PNC FINANCIAL SERVICES GROUP, INC. |
13F
|
Company |
0%
|
250
|
$1,123 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0%
|
51
|
$229 | — | 31 Mar 2024 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
0%
|
20
|
$90 | — | 31 Mar 2024 | |
| HUNTINGTON NATIONAL BANK |
13F
|
Company |
—
class O/S missing
|
1
|
$13 | — | 31 Mar 2024 |
Institutional Holders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) as of Q2 2024
As of 30 Jun 2024,
ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) was held by
73 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
51,801,951 shares.
The largest 10 holders included
Redmile Group, LLC, Prosight Management, LP, ORBIMED ADVISORS LLC, BlackRock Inc., MORGAN STANLEY, SILVERARC CAPITAL MANAGEMENT, LLC, GOLDMAN SACHS GROUP INC, PLATINUM INVESTMENT MANAGEMENT LTD, BANK OF AMERICA CORP /DE/, and Artal Group S.A..
This page lists
73
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
36
Q2 2024 holders
73
Holder diff
37
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.